Gemcitabine plus docetaxel versus docetaxel in patients with predominantly human epidermal growth factor receptor 2-negative locally advanced or metastatic breast cancer: a randomized, phase III study by the Danish Breast Cancer Cooperative Group

Dorte Lisbet Nielsen, Karsten D Bjerre, Erik H Jakobsen, Søren Cold, Lars Eric Stenbygaard, Peter G Sørensen, Claus Kamby, Susanne Møller, Charlotte L T Jørgensen, Michael Andersson

27 Citations (Scopus)

Abstract

The objective of this phase III study was to compare the efficacy of gemcitabine plus docetaxel (GD) versus docetaxel in patients with advanced breast cancer.
Original languageEnglish
JournalJournal of Clinical Oncology
Volume29
Issue number36
Pages (from-to)4748-54
Number of pages7
ISSN0732-183X
DOIs
Publication statusPublished - Dec 2011

Keywords

  • Adult
  • Aged
  • Antineoplastic Combined Chemotherapy Protocols
  • Breast Neoplasms
  • Deoxycytidine
  • Female
  • Humans
  • Middle Aged
  • Neoplasm Metastasis
  • Proportional Hazards Models
  • Receptor, erbB-2
  • Taxoids

Fingerprint

Dive into the research topics of 'Gemcitabine plus docetaxel versus docetaxel in patients with predominantly human epidermal growth factor receptor 2-negative locally advanced or metastatic breast cancer: a randomized, phase III study by the Danish Breast Cancer Cooperative Group'. Together they form a unique fingerprint.

Cite this